Impact of delays between clinical and laboratory standards institute and food and drug administration revisions of interpretive criteria for carbapenem-resistant Enterobacteriaceae

Sarah M. Bartsch, Susan S. Huang, Kim F. Wong, Rachel B. Slayton, James A. McKinnell, Daniel F. Sahm, Krystyna Kazmierczak, Leslie E. Mueller, John A. Jernigan, Bruce Y. Lee

Research output: Contribution to journalArticlepeer-review

Abstract

Delays often occur between CLSI and FDA revisions of antimicrobial interpretive criteria. Using our Regional Healthcare Ecosystem Analyst (RHEA) simulation model, we found that the 32-month delay in changing carbapenem-resistant Enterobacteriaceae (CRE) breakpoints might have resulted in 1,821 additional carriers in Orange County, CA, an outcome that could have been avoided by identifying CRE and initiating contact precautions. Policy makers should aim to minimize the delay in the adoption of new breakpoints for antimicrobials against emerging pathogens when containment of spread is paramount; delays of<1.5 years are ideal.

Original languageEnglish (US)
Pages (from-to)2757-2762
Number of pages6
JournalJournal of clinical microbiology
Volume54
Issue number11
DOIs
StatePublished - Nov 2016

ASJC Scopus subject areas

  • Microbiology (medical)

Fingerprint

Dive into the research topics of 'Impact of delays between clinical and laboratory standards institute and food and drug administration revisions of interpretive criteria for carbapenem-resistant Enterobacteriaceae'. Together they form a unique fingerprint.

Cite this